Beatwise The Podcast
Claim This Podcastby Sarah Birkhoelzer
Podcast Authority
Beta
Podcast Overview
<p>Welcome to <strong>Beatwise</strong> The Podcast, hosted by Dr. Sarah Birkhoelzer. </p><br><p>My mission is to bridge the gap between healthcare experts and patients, making cutting-edge medical research accessible and relevant to everyone. </p><br><p>Join me for engaging conversations, expert interviews, and practical advice that empower you to make informed decisions about your health and well-being. </p><br><p>Tune in to stay informed, inspired, and connected with the latest advancements in healthcare. </p><br><p>Let's build a healthier future together!</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Language
🇺🇲
Publishing Since
8/21/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Beatwise The Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 3, 2026
Episode #52: Cardiac Myosin Inhibitors in Obstructive Hypertrophic Cardiomyopathy
<p>In this episode of Beatwise The Podcast, I speak with Dr Brian Halliday about one of the biggest advances in the treatment of obstructive hypertrophic cardiomyopathy (HCM): cardiac myosin inhibitors.</p><br><p>For decades, treatment has focused on managing symptoms with medications such as beta blockers, verapamil and disopyramide, alongside septal reduction therapies for selected patients. We explore how cardiac myosin inhibitors represent a different approach by targeting the underlying hypercontractility that drives left ventricular outflow tract obstruction.</p><br><p>We discuss the science behind these therapies, how they work at a molecular level, and the evidence from landmark clinical trials including EXPLORER-HCM, VALOR-HCM and SEQUOIA-HCM. Dr Halliday explains what these studies have taught us about symptom improvement, exercise capacity, left ventricular outflow tract gradients and the potential to reduce the need for invasive septal reduction therapy.</p><br><p>We also discuss how these treatments are being introduced into clinical practice, including patient selection, specialist referral pathways, echocardiographic monitoring, and what the future may hold for patients with both obstructive and non-obstructive HCM.</p><br><p><strong>Key issues addressed:</strong></p><ul><li>Traditional treatment options for obstructive HCM</li><li>How cardiac myosin inhibitors work</li><li>The evidence from EXPLORER-HCM, VALOR-HCM and SEQUOIA-HCM</li><li>Myosin inhibitors versus beta blockers</li><li>Referral pathways, monitoring and prescribing in the UK</li><li>Future directions for HCM treatment</li></ul><p><br></p><p>Whether you care for patients with HCM or live with the condition yourself, this episode provides an overview of how treatment is evolving and what these new therapies may mean for the future.</p><br><p><strong>EPISODE HIGHLIGHTS:</strong></p><p>00:00 Welcome and episode focus</p><p>01:02 Traditional HCM treatments</p><p>02:46 How myosin inhibitors work</p><p>06:26 Landmark mavacamten trials</p><p>10:23 Aficamten and new evidence</p><p>11:45 Beta blockers versus myosin inhibitors</p><p>16:19 Referral pathways and monitoring</p><p>20:33 NHS prescribing and echocardiographic follow-up</p><p>21:42 Future of HCM treatment</p><p>23:44 Wrap up</p><p>24:35 Final thanks and subscribe</p><br><p>If you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.</p><br><p>Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
June 12, 2026
Episode #51: The Shared Pillars of Cardiorenal Care
<p>Heart failure, chronic kidney disease (CKD) and metabolic disease are deeply interconnected, yet healthcare systems have traditionally treated them as separate conditions. In this episode of Beatwise, I’m joined by Dr Andrew Frankel, Consultant Nephrologist at Imperial College Healthcare NHS Trust, to explore why cardiorenal metabolic (CRM) medicine is transforming how we care for patients.</p><br><p>We discuss the shared biology linking heart, kidney and metabolic disease, why "creatinine fear" continues to prevent optimal treatment, and how therapies such as SGLT2 inhibitors, finerenone and GLP-1 receptor agonists are reshaping outcomes across multiple specialties.</p><br><p>We also explore the future of integrated cardiorenal care, including multidisciplinary services, workforce education, patient-centred CRM hubs and what healthcare systems need to do next to improve outcomes while reducing fragmentation of care.</p><br><p>Key topics discussed: </p><ul><li>Why cardiorenal metabolic disease should be viewed as a single disease process rather than separate conditions</li><li>The common pathophysiology linking heart failure, CKD and metabolic disease</li><li>The problem with "creatinine fear" and premature discontinuation of life-saving therapies</li><li>The four pillars of modern cardiorenal metabolic treatment</li><li>Practical prescribing tips for SGLT2 inhibitors, including eGFR thresholds and sick day rules</li><li>Hyperkalaemia as a barrier to guideline-directed medical therapy and how to overcome it</li><li>The role of finerenone and non-steroidal MRAs in cardiorenal care</li><li>Why GLP-1 receptor agonists offer benefits far beyond weight loss</li><li>How integrated cardiorenal services can improve patient outcomes and reduce healthcare costs</li><li>The future of CRM hubs and one-stop multidisciplinary care pathways</li></ul><p><br></p><p>About my guest:</p><p>Dr Andrew Frankel is a Consultant Nephrologist at Imperial College Healthcare NHS Trust and a leading advocate for integrated kidney care, cardiorenal medicine and workforce education. He is also co-host of the educational podcast <a href="https://www.forkidneyssake.com/" rel="noopener noreferrer" target="_blank">For Kidneys' Sake</a>, which provides practical updates on chronic kidney disease and cardiorenal metabolic care.</p><br><p><strong>EPISODE HIGHLIGHTS:</strong></p><p>00:00 Welcome and Guest Introduction</p><p>01:29 Why Cardiorenal Medicine Matters</p><p>03:14 Creatinine Fear and GFR Misconceptions</p><p>04:31 The Four Pillars of Cardiorenal Therapy</p><p>07:53 Practical Use of SGLT2 Inhibitors</p><p>10:58 Hyperkalaemia as a Barrier to Treatment</p><p>14:22 Building Integrated Cardiorenal Services</p><p>19:04 Specialist Roles and Shared Care</p><p>20:40 GLP-1 Receptor Agonists and New Weight-Loss Therapies</p><p>23:33 Lifestyle Medicine and CRM Hubs</p><p>26:28 Closing Reflections</p><p>28:41 Final Thanks and Subscribe</p><br><p>If you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.</p><br><p>Don't forget to follow me on social media @<a href="https://www.instagram.com/sarah.theheartdoc/" rel="noopener noreferrer" target="_blank">sarah.theheartdoc</a> for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
May 22, 2026
Episode #50: Inside the RESOLVE-HCM Trial: A New Approach to Non-Obstructive HCM
<p>In this episode of BeatWise The Podcast, I am joined by Professor Joseph Selvanayagam to explore cardiac metabolism in hypertrophic cardiomyopathy (HCM), the evolving treatment landscape in HCM, and the findings of the RESOLVE-HCM trial investigating perhexiline in non-obstructive disease.</p><br><p>We explore the heterogeneity of HCM, including the differences between obstructive and non-obstructive forms of the condition, why symptoms are not always explained by LV outflow tract obstruction alone, and how treatment strategies are beginning to move beyond symptom management toward disease-modifying therapies.</p><br><p>We also discuss the role of myocardial energetics and metabolic dysfunction in HCM, how perhexiline works as a CPT1 inhibitor to shift myocardial metabolism toward more oxygen-efficient glucose use, and why this may be particularly relevant in non-obstructive HCM where treatment options remain limited.</p><br><p>Professor Selvanayagam takes us inside the design of the randomized, double-blind RESOLVE-HCM trial, including the use of cardiac MRI imaging and maximal LV wall thickness as the primary endpoint over 12 months. We review the trial findings, where several endpoints including diastolic function, NT-proBNP, and quality-of-life measures favored perhexiline, with mental health quality-of-life outcomes reaching statistical significance.</p><br><p>We also explore the importance of therapeutic drug monitoring given perhexiline’s narrow therapeutic index, the risks of hepatotoxicity and neurotoxicity, and the future direction of metabolic therapies in cardiomyopathy.</p><br><p>Key topics discussed: </p><ul><li>Obstructive vs non-obstructive HCM</li><li>What drives symptoms in hypertrophic cardiomyopathy</li><li>The evolution of HCM therapies</li><li>Cardiac metabolism and myocardial energetics</li><li>How perhexiline works</li><li>The RESOLVE-HCM trial</li><li>Cardiac MRI endpoints in HCM research</li><li>Therapeutic drug monitoring and safety</li><li>Disease-modifying therapies in cardiomyopathy</li></ul><p><br></p><p><strong>EPISODE HIGHLIGHTS:</strong></p><p>00:00 Welcome to Beatwise</p><p>00:27 Why metabolism matters</p><p>01:59 Meet Professor Selvanayagam</p><p>02:29 HCM types and symptoms</p><p>04:29 Treatment landscape update</p><p>05:42 Why RESOLVE-HCM</p><p>07:20 How perhexiline works</p><p>08:44 Trial design and imaging</p><p>12:53 RESOLVE-HCM results</p><p>14:43 Clinical use and safety</p><p>17:15 Future trials and wrap up</p><p>18:54 Final takeaways</p><br><p>If you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.</p><br><p>Don't forget to follow me on social media @<a href="https://www.instagram.com/sarah.theheartdoc/" rel="noopener noreferrer" target="_blank">sarah.theheartdoc</a> for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
53 total episodes available
Recent guests on Beatwise The Podcast
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Dr John Ostrominski
Guest
Dr Emily Haseler
Guest
Professor Charlotte Manisty
Guest
Dr. Ellen Fallows
Guest
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Beatwise The Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Beatwise The Podcast?
<p>Welcome to <strong>Beatwise</strong> The Podcast, hosted by Dr. Sarah Birkhoelzer. </p><br><p>My mission is to bridge the gap between healthcare experts and patients, making cutting-edge medical research accessible and relevant to everyone. </p><br><p>Join me for engaging conversations, expert interviews, and practical advice that empower you to make informed decisions about your health and well-being. </p><br><p>Tune in to stay informed, inspired, and connected with the latest advancements in healthcare. </p><br><p>Let's build a healthier future together!</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.